Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novozymes Biopharma to Showcase World Leading Products at CPhI China

Published: Wednesday, May 29, 2013
Last Updated: Wednesday, May 29, 2013
Bookmark and Share
Innovative range of Hyaluronic Acid, recombinant albumin and enzymes for biocatalysis to be presented alongside insight into China investment.

For the first time, Novozymes Biopharma will showcase its biological-based ingredients and technologies at CPhI China.

The company’s Hyasis™, Recombumin® and biocatalysis products will feature at the pharmaceutical ingredients event, taking place in Shanghai from June 24 - 27 2013.

Importantly, visitors will also have the chance to hear Amber Deng Yue, Regional Marketing Manager for Novozymes Biopharma, present an introduction to the company and its continued investment in operations in China.

“Hyaluronic acid and albumin have significant roles to play in the future of drug development, both in the Chinese market and worldwide,” comments Hemant Pachnanda, business development director at Novozymes Biopharma.

“As the world’s first and only supplier of animal-free recombinant albumins, Recombumin® Prime and Recombumin® Alpha, we work closely with our partners to deliver safe, stable formulations. Recombumin® leads the market in excipients for liquid drug and vaccine formulations, and users can be sure of superior cGMP quality, regulatory support and long-term supply.”

Hyasis® is the next generation of high-quality hyaluronic acid, based on the safe bacteria Bacillus subtilis. Superior heat stability and rapid dissolving time, together with exceptional bath-to-batch consistency characterize the product.

Hyasis® expands the number of possible applications of hyaluronic acid in medical device and pharma products. Novozymes’ Hyasis can be customized further using the company’s proprietary crosslinking technology to achieve a specified viscosity.

This enables the product to be adapted for a wide range of drug delivery and medical device applications including ophthalmology, dermal fillers, osteoarthritis, adhesion prevention, coating and wound healing.

Biocatalysis is an enabling technology which can help pharmaceutical and intermediate manufacturers achieve enhanced sustainability performance, energy cost savings, and decreased raw material costs.

The range of commercial lipases and proteases can be used in chemical transformations in Active Pharmaceutical Ingredient (API) as well as intermediate manufacturing, offering unique advantages.

These include high levels of regioselectivity and stereo selectivity in chemical reactions, reducing the length of the process and the use of expensive, toxic raw materials.

The selection of lipases includes Candida Antartica Lipase B (Lipozyme®CALB L), Candida Antartica Lipase A (NovoCor®AD L), immobilized lipases such as Novozym® 435 and proteases like Alcalase® and Savinase®.

The showcase presentations will take place in the Showcase Area in the exhibition hall at the following timings - 10:00-10:20 for Jun 25th and Jun 26th.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novozymes Expands Collaboration with Upperton Limited
Conjugating Recombumin® Flex to drugs offers the opportunity to dramatically enhance patient lives and drive down healthcare costs.
Friday, December 09, 2011
Novozymes Biopharma to Present on Creating Market Opportunities Through Drug Half-Life Extension at 2011 BIO Business Forum
Panel session and presentation will explore half-life extension technologies designed to overcome challenges associated with the therapeutic use of peptides and proteins.
Friday, June 24, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!